Oncology Adjuvants Market Size & Share, by Application (Radiotherapy, Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy); Indication (Sarcoma, Breast Cancer, Colorectal Cancer, Glioblastoma, Prostate Cancer, Lung Cancer, Ovarian Cancer); End User (Cancer Research Institute, Cancer Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5860
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Oncology Adjuvants Market size is expected to reach USD 4 billion by the end of 2036, growing at a CAGR of 5% during the forecast period i.e., 2024-2036. In the year 2023, industry size of oncology adjuvants was USD 1 billion. A major driver for the global market is the increasing incidence of cancer worldwide. As cancer cases proceed to extend, there's a developing request for successful treatment choices, counting adjuvant treatments that can progress persistent results. Considering WHO's factsheet of February 2022, cancer is one of the driving causes of passing, which killed 10 million deaths in 2020, which is one in six deaths. 

Complementary adjuvant treatments have become necessary due to the development of innovative and targeted treatments for different types of cancer. In order to enhance their effectiveness and reduce the risk of recurrence, adjuvant medicinal products are used for primary cancer treatment such as surgery, chemotherapy or radiation therapy. Technological advances in drug delivery systems and formulations are also contributing to the market for Oncology Adjuvants. The potential applications of adjuvants have been expanded by the development of targeted drug delivery systems, immunotherapies, and personalized medicine approaches, which have led to increased market demand.


Oncology Adjuvants Market
Get more information on this report: Request Free Sample PDF

Oncology Adjuvants Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Number of Cancer Research Institutes - In cancer research institutes, there is extensive use of adjunctive chemotherapy. This treatment helps patients with cancer fight. The treatment helps to improve the effectiveness of therapy and reduce adverse reactions. Market growth is expected to be driven by an increase in the number of cancer centers worldwide, as well as a growing need for safe and effective treatment of patients with cancer. The chemotherapy treatment helps to increase the response rate. In the coming years, these factors are expected to stimulate growth in this market. The growth of the oncology adjuvants market is expected to be driven by ongoing research in cancer institute’s towards developing more advanced technology.
  • Huge Government Funding for Development of Healthcare Infrastructure - Market growth is expected to be driven by a high adoption of new technologies and an increase in government funding for cancer research and hospital care. In addition, market growth is expected to be driven by the presence of a well-developed healthcare infrastructure and the availability of advanced healthcare equipment. Increasing per capita healthcare costs and the rapid development of health infrastructure. The oncology adjuvants market is expected to grow over the forecast period, driven by growing numbers of professionals who prefer this medicine for improving efficiency and reducing toxicity levels.

Challenges

  • High Costs and Reimbursements Issues- Oncology Adjuvants such as many cancer treatments can be very expensive. This puts a strain on healthcare systems and limits patient access, especially in regions with limited resources. Reimbursement policies from insurance companies can also be complex and restrictive, further hindering affordability.
  • Evolving regulatory landscape is expected to hinder the market growth in the upcoming period
  • Presence of alternatives is expected to pose limitation on the oncology adjuvants market expansion in the forecast period.

Oncology Adjuvants Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~5%

Base Year Market Size

~USD 1 billion

Forecast Year Market Size

~USD 4 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Oncology Adjuvants Segmentation

Indication (Sarcoma, Breast Cancer, Colorectal Cancer, Glioblastoma, Prostate Cancer, Lung Cancer, Ovarian Cancer)

Based on indication, the breast cancer segment is predicted to account for 15% share of the global oncology adjuvants market during the forecast period. The growth of this segment can be attributed to the back of increasing prevalence of breast cancer. As per data generated by WHO, in 2020 around 2.3 million women were diagnosed with breast cancer and 685000 individuals lost their life due to this disease. Breast cancer is one of the foremost common sorts of cancer among ladies all-inclusive, and adjuvant treatments play a vital part in overseeing and treating this malady. Adjuvant treatments in breast cancer are utilized after essential treatment, regularly including surgery to evacuate the tumor. The essential objective of adjuvant treatments in breast cancer is to decrease the hazard of cancer repeat and make strides in long-term survival rates. They are managed to target any remaining cancer cells that will not have been killed by surgery and to anticipate the spread of cancer cells to other parts of the body. 

End User (Cancer Research Institute, Cancer Hospitals)

In terms of end user, the cancer hospital segment is predicted to account for 80% share of the global oncology adjuvants market by 2036. Market growth is expected to be driven by increasing demand for cancer hospitals around the world.  Lung cancer, colon cancer, prostate cancer, breast cancer, and other forms of gynecological cancers are treated in cancer hospitals. It helps to reduce the recurrence of cancer by treating it effectively. By increasing the effectiveness of primary therapy, cancer hospitals have been increasingly using this approach in improving patient outcomes. In order to improve the overall effectiveness of therapy, it is used. Market growth is also expected to be driven by increased funding for cancer research and an increase in the incidence of cancer around the world. The product is typically a drug that is used along with primary cancer treatments such as radiation therapy, surgery, and chemotherapy. In the coming years, these factors are expected to accelerate market developments.

Our in-depth analysis of the global market includes the following segments:

         Application

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  •  Hormone Therapy
  •  Targeted Therapy

         Indication

  • Sarcoma
  • Breast Cancer
  •  Colorectal Cancer
  •  Glioblastoma
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer

          End User

  • Cancer Research Institute
  • Cancer Hospitals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Oncology Adjuvants Industry - Regional Synopsis

North American Market Forecasts

The market in the North America region is predicted to hold the highest CAGR of 35% during the prediction period. Factors such as the rising incidence of cancer, a large patient population, good healthcare facilities, and an emphasis on research and development can be attributed to this growth. In 2019, in the United States, it was reported that there were 1,752,735 new cancer cases recorded, and 599,589 individuals died from cancer reported as of the Center for Disease Control and Prevention statistics of June 2022. In addition, significant advances in healthcare technology and innovation have been made in North America. There is an established pharmaceutical and biotechnology sector in the region that contributes to developing new adjuvants and targeted treatments. The market growth is also supported by the adoption of advanced drug delivery systems and personalized approaches to medicine.

APAC Market Statistics

The market in the Asia Pacific region is set to grow notably during the time period between 2024- 2036. This growth can be attributed to an increase in per capita healthcare expenditure due to higher quality. The market opportunities are expected to be expanded by increasing R&D initiatives and increased demand for cancer treatments in this area. Moreover, the market's growth is supported by a growing number of cancer hospitals and an increased acceptance of new technology.

Research Nester
Oncology Adjuvant Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Oncology Adjuvants Landscape

top-features-companies
    • Sanofi S.A
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    •  Amgen Inc.
    • Bristol Myers Squibb
    • Eli Lilly and Company
    • Biogen AstraZeneca plc
    • Pfizer Inc.
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • SL Pharmaceutical
    • Sanjiu Medical
    • Hisun Pharmaceuticals USA Inc.

In-the-news

In The News

  • The benefit and feasibility of a novel approach to surgical treatment in NSCLC was demonstrated by the AEGEAN trial in June 2021. In patients with non-small cell lung cancer, combining neoadjuvant durvalumab with platinum-based chemotherapy, taken after by curative-intent surgery and adjuvant durvalumab progressed antitumor action and diminished repeat chance. In addition, perioperative durvalumab increased the rate of pathologic complete response by 12.9% when compared to placebo.
  • Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5860
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of cancer and increasing number of cancer research intitutes are some of the major factors anticipated to drive the growth of the oncology adjuvant market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company, Biogen AstraZeneca plc, Pfizer Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., and others.

The cancer hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Oncology Adjuvants Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying